子痫前期预测:未来之路
子痫前期是异质性综合征而非单一疾病,其表现和病理生理不同,可能提示不同表型,且影响超越妊娠本身,对胎儿和母亲的影响持续多年。现有预测方法因异质性受阻,低剂量阿司匹林或全局抗氧化剂等治疗尝试未成功。未来需识别表型以实现特异性预测和治疗,需国际协作统一数据与标本采集标准,并纳入低资源和高资源环境女性,利用机器学习和人工智能。
要点
- 子痫前期是异质性综合征,不同表型需特异性预测和治疗。
- 现有预测方法因异质性受限,低剂量阿司匹林等治疗未成功。
- 未来研究需国际协作统一数据标准,并应用机器学习与人工智能。
核心结论
- 子痫前期是异质性综合征,需识别不同表型以实现特异性预测和治疗。
研究设计与样本
- 原文为综述/观点类文章,未报告系统检索范围或样本量。
主要发现
- 子痫前期表现和病理生理异质,可能提示不同表型。
- 子痫前期对胎儿和母亲的影响持续多年,胎儿编程成人疾病并增加母亲心血管疾病风险。
- 有既存危险因素的女性中子痫前期发生增加,提示妊娠应激可能暴露亚临床血管疾病。
- 异质性阻碍了妊娠早期预测子痫前期的努力,也使低剂量阿司匹林或全局抗氧化剂等治疗尝试未成功。
临床怎么用
- 临床应认识到子痫前期是异质性综合征,不同表型可能需要不同预测和治疗策略。
- 未来研究需国际协作统一临床数据和生物标本采集标准,并应用机器学习和人工智能。
局限性
- 原文未报告具体研究设计、样本量或系统检索范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite intensive investigation, we still cannot adequately predict, treat, or prevent preeclampsia. We have gained awareness that preeclampsia is a syndrome not a disease and is heterogeneous in its presentation and pathophysiology, which may indicate differing underlying phenotypes, and that the impact extends beyond pregnancy per se. Effects on the fetus and mother extend many years after pregnancy, as evidenced by fetal programming of adult disease and increased risk of the development of maternal cardiovascular disease. The increased occurrence of preeclampsia in women with preexisting risk factors suggests that the stress of pregnancy may expose subclinical vascular disease as opposed to preeclampsia damaging the vasculature. The heterogeneity of preeclampsia has blighted efforts to predict preeclampsia early in gestation and has thwarted success in attempts at therapy with treatments, such as low-dose aspirin or global antioxidants. There is a critical need to identify the phenotypes to enable their specific prediction and treatment. Such studies require considerably larger collections of patients than employed in past and current studies. This does not necessarily imply much larger patient numbers in single studies but can be facilitated by the ability to easily combine many smaller studies. This can be accomplished by agreeing on a priori standardized and harmonized clinical data and biospecimen collection across new studies. Such standards are being established by international groups of investigators. Leadership by international organizations, perhaps adopting a carrot and stick approach, to overcome investigator, institutional and funder reticence toward data sharing is required to ensure adoption of such standards. Future studies should include women in both low- and high-resource settings and employ social media and novel methods for data collection and analysis, including machine learning and artificial intelligence. The goal is to identify the pathophysiology underlying differing preeclampsia phenotypes, their successful prediction with the design, and the implementation of phenotype-specific therapies.
引用
- Myatt L. The prediction of preeclampsia: the way forward. Am J Obstet Gynecol. 2021. PMID: 33785181. doi:10.1016/j.ajog.2020.10.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。